Hamlet BioPharma

An innovative pharmaceutical company with a broad portfolio of projects for the treatment of cancer and infections.

[Hamlet BioPharma @HamletBioPharma]

Exciting news!
HAMLET BioPharma has signed a Letter of Intent with a German uro-oncology partner on a potential collaboration for Alpha1H in bladder cancer. Alpha1H has FDA Fast Track and clearance for a pivotal Phase III study. 🧬🤝

Read more: https://t.co/ftrBIHFD7q

[Hamlet BioPharma @HamletBioPharma]

🎉Our Founder, Prof. Catharina Svanborg, is featured in @FemestMag, sharing HAMLET BioPharma's story and our journey from discovery to clinic.

Plus: new highlights on novel non-antibiotic infection therapies presented at @biozentrum Basel.

Read more: https://t.co/7QnsT1mQCi

[Hamlet BioPharma @HamletBioPharma]

🗞️📊Please see Hamlet BioPharma’s Q2 Interim Report (Oct–Dec 2025).

We highlight the exciting progress we’ve made and are focused on what’s ahead:

🔗 Link to the press release: https://t.co/DxwYOgFN8z

[Hamlet BioPharma @HamletBioPharma]

🔗Link to the press release: https://t.co/sOHHMvhCWh

[Hamlet BioPharma @HamletBioPharma]

🚨The leading international journal Nature Microbiology has published our latest paper! 🧬

Title -
Targeted innate immune inhibition therapy compared with antibiotics for recurrent acute cystitis: a randomized, open-label phase 2 trial.

🔗 Article link: https://t.co/62ICeHCN81

[Hamlet BioPharma @HamletBioPharma]

🔬We’re hosting a one-day symposium on novel treatments for infections & cancer!
🗓 28 Jan 2026 | 📍 Belfragesalen, BMC, Lund

Talks by international experts + panel discussions.

#ScientificSymposium #CancerResearch #InfectiousDiseases #BiomedicalResearch #NovelTherapies

[Hamlet BioPharma @HamletBioPharma]

🎯 Major milestone: Hamlet BioPharma receives FDA feedback supporting a pivotal study for Alpha1H, our first-in-class therapy for early-stage bladder cancer.

Read more 👉https://t.co/AdlCXoFIxW

#FDA #CancerResearch #Oncology #Biotechnology #ClinicalTrials